HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
Status:
Not yet recruiting
Trial end date:
2023-04-14
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and
efficacy of HM15136 when used as add-on therapy in subjects with CHI with persistent
hypoglycemia while on standard of care treatment (SoC). HM15136 will be administered once
weekly in multiple doses to subjects in multiple age including pediatric to find appropriate
exposure-response data.